Vertex Pharmaceuticals (VRTX) Earns Daily News Impact Score of 0.21
Media stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the pharmaceutical company an impact score of 45.2180668821234 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX) – Lookout for Volatility – Stock Watch (stocksnewstimes.com)
- Investors need to focus on Analysts Rating: Vertex Pharmaceuticals Incorporated (VRTX) – Wall Street Morning (wallstreetmorning.com)
- Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in Stock (americanbankingnews.com)
- Vertex to Present at the Cowen Healthcare Conference on March 13 (finance.yahoo.com)
- Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million (americanbankingnews.com)
A number of brokerages have commented on VRTX. Bank of America lifted their price target on Vertex Pharmaceuticals from $180.00 to $197.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. HC Wainwright reissued a “hold” rating and issued a $103.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. BidaskClub raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. Leerink Swann reaffirmed an “outperform” rating and issued a $190.00 price target (up previously from $175.00) on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Finally, JMP Securities reiterated an “outperform” rating and set a $211.00 price objective (up from $200.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and twenty-five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $183.96.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The company had revenue of $651.63 million during the quarter, compared to the consensus estimate of $592.49 million. During the same period last year, the firm earned $0.35 EPS. The company’s revenue for the quarter was up 42.1% on a year-over-year basis. equities analysts forecast that Vertex Pharmaceuticals will post 1.67 EPS for the current year.
Vertex Pharmaceuticals announced that its board has approved a stock buyback program on Wednesday, January 31st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the pharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.
In other news, EVP Amit Sachdev sold 13,750 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $175.00, for a total transaction of $2,406,250.00. Following the completion of the sale, the executive vice president now directly owns 60,412 shares of the company’s stock, valued at approximately $10,572,100. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Graney sold 777 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total transaction of $116,511.15. The disclosure for this sale can be found here. Insiders sold a total of 356,966 shares of company stock valued at $57,081,624 over the last ninety days. 1.80% of the stock is owned by corporate insiders.
WARNING: This piece was posted by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.mareainformativa.com/2018/03/14/vertex-pharmaceuticals-vrtx-receives-daily-media-sentiment-rating-of-0-21-updated-updated-updated.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.